Incidence of diabetes mellitus and neoplasia in japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Susumu Yokoya, Tomonobu Hasegawa, Keiichi Ozono, Hiroyuki Tanaka, Susumu Kanzaki, Toshiaki Tanaka, Kazuo Chihara, Nan Jia, Christopher J. Child, Katsuichiro Ihara, Jumpei Funai, Noriyuki Iwamoto, Yoshiki Seino

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The primary goal of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) was to assess the safety and effectiveness of Humatrope®, a GH preparation, in the treatment of pediatric patients with short stature. We report our findings in the GH-treated Japanese pediatric population focusing on the incidence of type 2 diabetes (T2D) and occurrence of neoplasms. A total of 2,345 Japanese patients were assessed for safety. During a mean observation period of 3.2 yr, T2D occurred in 3 patients (0.13%) and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) related to underlying mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in 1 patient (0.04%). Neoplasms were reported in 13 patients (0.56%), including 1 patient with brain tumor (germinoma) and 5 with craniopharyngiomas (4 recurrences); the remainder were benign, typically dermatological, neoplasms. The incidence of diabetes mellitus determined in the study did not differ from previous reports in GH-treated pediatric patients, and there was no apparent increase in the risk of new neoplastic lesions or malignant tumors.

Original languageEnglish
Pages (from-to)229-241
Number of pages13
JournalClinical Pediatric Endocrinology
Volume26
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Neuroendocrinology
Growth Hormone
Diabetes Mellitus
Incidence
Neoplasms
Pediatrics
Type 2 Diabetes Mellitus
MELAS Syndrome
Germinoma
Safety
Craniopharyngioma
Human Growth Hormone
Type 1 Diabetes Mellitus
Brain Neoplasms
Observation
Recurrence

Keywords

  • Diabetes mellitus
  • Neoplasia
  • Pediatric GH treatment
  • Safety
  • Short stature

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Incidence of diabetes mellitus and neoplasia in japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS). / Yokoya, Susumu; Hasegawa, Tomonobu; Ozono, Keiichi; Tanaka, Hiroyuki; Kanzaki, Susumu; Tanaka, Toshiaki; Chihara, Kazuo; Jia, Nan; Child, Christopher J.; Ihara, Katsuichiro; Funai, Jumpei; Iwamoto, Noriyuki; Seino, Yoshiki.

In: Clinical Pediatric Endocrinology, Vol. 26, No. 4, 2017, p. 229-241.

Research output: Contribution to journalArticle

Yokoya, Susumu ; Hasegawa, Tomonobu ; Ozono, Keiichi ; Tanaka, Hiroyuki ; Kanzaki, Susumu ; Tanaka, Toshiaki ; Chihara, Kazuo ; Jia, Nan ; Child, Christopher J. ; Ihara, Katsuichiro ; Funai, Jumpei ; Iwamoto, Noriyuki ; Seino, Yoshiki. / Incidence of diabetes mellitus and neoplasia in japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS). In: Clinical Pediatric Endocrinology. 2017 ; Vol. 26, No. 4. pp. 229-241.
@article{e2a7287b0e8c4e72a7dadd30440d085b,
title = "Incidence of diabetes mellitus and neoplasia in japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)",
abstract = "The primary goal of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) was to assess the safety and effectiveness of Humatrope{\circledR}, a GH preparation, in the treatment of pediatric patients with short stature. We report our findings in the GH-treated Japanese pediatric population focusing on the incidence of type 2 diabetes (T2D) and occurrence of neoplasms. A total of 2,345 Japanese patients were assessed for safety. During a mean observation period of 3.2 yr, T2D occurred in 3 patients (0.13{\%}) and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) related to underlying mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in 1 patient (0.04{\%}). Neoplasms were reported in 13 patients (0.56{\%}), including 1 patient with brain tumor (germinoma) and 5 with craniopharyngiomas (4 recurrences); the remainder were benign, typically dermatological, neoplasms. The incidence of diabetes mellitus determined in the study did not differ from previous reports in GH-treated pediatric patients, and there was no apparent increase in the risk of new neoplastic lesions or malignant tumors.",
keywords = "Diabetes mellitus, Neoplasia, Pediatric GH treatment, Safety, Short stature",
author = "Susumu Yokoya and Tomonobu Hasegawa and Keiichi Ozono and Hiroyuki Tanaka and Susumu Kanzaki and Toshiaki Tanaka and Kazuo Chihara and Nan Jia and Child, {Christopher J.} and Katsuichiro Ihara and Jumpei Funai and Noriyuki Iwamoto and Yoshiki Seino",
year = "2017",
doi = "10.1297/cpe.26.229",
language = "English",
volume = "26",
pages = "229--241",
journal = "Clinical Pediatric Endocrinology",
issn = "0918-5739",
publisher = "Jeff Corporation Co. Ltd",
number = "4",

}

TY - JOUR

T1 - Incidence of diabetes mellitus and neoplasia in japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

AU - Yokoya, Susumu

AU - Hasegawa, Tomonobu

AU - Ozono, Keiichi

AU - Tanaka, Hiroyuki

AU - Kanzaki, Susumu

AU - Tanaka, Toshiaki

AU - Chihara, Kazuo

AU - Jia, Nan

AU - Child, Christopher J.

AU - Ihara, Katsuichiro

AU - Funai, Jumpei

AU - Iwamoto, Noriyuki

AU - Seino, Yoshiki

PY - 2017

Y1 - 2017

N2 - The primary goal of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) was to assess the safety and effectiveness of Humatrope®, a GH preparation, in the treatment of pediatric patients with short stature. We report our findings in the GH-treated Japanese pediatric population focusing on the incidence of type 2 diabetes (T2D) and occurrence of neoplasms. A total of 2,345 Japanese patients were assessed for safety. During a mean observation period of 3.2 yr, T2D occurred in 3 patients (0.13%) and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) related to underlying mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in 1 patient (0.04%). Neoplasms were reported in 13 patients (0.56%), including 1 patient with brain tumor (germinoma) and 5 with craniopharyngiomas (4 recurrences); the remainder were benign, typically dermatological, neoplasms. The incidence of diabetes mellitus determined in the study did not differ from previous reports in GH-treated pediatric patients, and there was no apparent increase in the risk of new neoplastic lesions or malignant tumors.

AB - The primary goal of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) was to assess the safety and effectiveness of Humatrope®, a GH preparation, in the treatment of pediatric patients with short stature. We report our findings in the GH-treated Japanese pediatric population focusing on the incidence of type 2 diabetes (T2D) and occurrence of neoplasms. A total of 2,345 Japanese patients were assessed for safety. During a mean observation period of 3.2 yr, T2D occurred in 3 patients (0.13%) and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) related to underlying mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in 1 patient (0.04%). Neoplasms were reported in 13 patients (0.56%), including 1 patient with brain tumor (germinoma) and 5 with craniopharyngiomas (4 recurrences); the remainder were benign, typically dermatological, neoplasms. The incidence of diabetes mellitus determined in the study did not differ from previous reports in GH-treated pediatric patients, and there was no apparent increase in the risk of new neoplastic lesions or malignant tumors.

KW - Diabetes mellitus

KW - Neoplasia

KW - Pediatric GH treatment

KW - Safety

KW - Short stature

UR - http://www.scopus.com/inward/record.url?scp=85030257909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030257909&partnerID=8YFLogxK

U2 - 10.1297/cpe.26.229

DO - 10.1297/cpe.26.229

M3 - Article

AN - SCOPUS:85030257909

VL - 26

SP - 229

EP - 241

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

SN - 0918-5739

IS - 4

ER -